News | May 10, 2021
Sun Pharma signs agreement with Eli Lilly for expanding access to Baricitinib
Baricitinib is used in combination with remdesivir for the treatment of suspected or laboratory confirmed COVID-19
Baricitinib is used in combination with remdesivir for the treatment of suspected or laboratory confirmed COVID-19
Baricitinib is an oral medication that was earlier registered in India for the treatment of moderate to severe active rheumatoid arthritis in adult patients.
_256_384.jpg)
Tirzepatide is the first and only dual agonist glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors
Excelsior aims to make reshoring affordable and strategic, shielding nations from geopolitical disruptions
Enabling a new era in minimally invasive obesity treatment across Europe
Sales from Novo’s GLP-1 portfolio—including Wegovy for obesity and Ozempic for type 2 diabetes reached $5.6 billion
The deal reinforces GSK’s leadership in respiratory care and builds upon the company’s expanding COPD portfolio
New test expands access to early Alzheimer’s assessment, streamlining diagnostic pathways and improving referral efficiency
Drug Hunter is already relied upon by researchers at more than 200 leading organizations, including Eli Lilly, Biogen, Merck KGaA, Isomorphic Labs, Deerfield Management
Rhonda Pacheco to succeed Julie Kim, who was appointed to be Takeda’s next CEO
Subscribe To Our Newsletter & Stay Updated
